ReachRxResearch
Home
Research
Sign Up
Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial
Back to Research Hub
  1. Home
  2. Research Hub
  3. Efficacy and safety of oral orforglipron…

Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial

The Lancet Diabetes & Endocrinology·October 30
Endocrinology & MetabolismPractice changingObesityRandomized Controlled TrialGLP-1 Receptor AgonistOral Small MoleculeAdultOlder AdultOrforglipron

Summary

View source

What was studied

This phase 3 RCT evaluated once-daily oral orforglipron (6 mg, 12 mg, or 36 mg) vs placebo over 72 weeks in 238 Japanese adults with obesity disease (BMI 27–<35 kg/m² with ≥2 comorbidities, or BMI ≥35 kg/m² with ≥1 comorbidity), with co-primary endpoints of mean % bodyweight change and proportion achieving ≥5% bodyweight reduction.

Key findings

At 72 weeks, mean bodyweight reductions were -5.9% (6 mg), -8.7% (12 mg), and -7.9% (36 mg) vs -0.6% with placebo (all p<0.0001); ≥5% bodyweight loss was achieved by 45.6%, 60.8%, and 58.8% of participants in the orforglipron groups, respectively, vs 15.2% with placebo.

Study limitations

Single-ethnicity (Japanese) sample limits generalizability; the trial included a relatively narrow BMI range aligned with Japanese regulatory definitions; no active comparator arm (e.g., semaglutide or tirzepatide) was included.

Clinical implications

Oral orforglipron at all three doses produced clinically meaningful, statistically superior weight loss vs placebo in Japanese adults with obesity, with a gastrointestinal side-effect profile typical of GLP-1 receptor agonists; the 12 mg dose showed the greatest mean weight reduction (-8.7%).

Caveats

  • All participants were Japanese adults; results may not generalize to other ethnic populations given known differences in metabolic risk profiles and BMI thresholds
  • Approximately 25% of participants had type 2 diabetes, which may influence weight-loss outcomes compared to a purely non-diabetic obesity population
  • No active comparator was used, so relative efficacy versus approved agents (semaglutide, tirzepatide) in this population cannot be determined from this trial
Show all 4
  • Weight loss effect sizes (-5.9% to -8.7%) are more modest than those reported in global orforglipron phase 3 trials in predominantly non-Asian populations, suggesting possible ethnic or BMI-range differences

Related Questions

Explore related topics

What are the weight loss outcomes of oral orforglipron compared to injectable semaglutide or tirzepatide?How does orforglipron's gastrointestinal side-effect profile compare to other GLP-1 receptor agonists for obesity?What are the cardiovascular and cardiometabolic outcomes of orforglipron in adults with obesity?

Publication Details

Year
2026
Journal
The Lancet Diabetes &amp; Endocrinology
Sample Size
n=238
Source
View article
Keep scrolling
More content below.
Up Next